Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp


Perjeta®, pertuzumab, is approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people who have HER2 positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti HER2 therapy or chemotherapy for metastatic breast cancer.

Perjeta® is approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:

To Read More>>

To get a personal free assessment to our service please in fill in your details and we will get back to you shortly

Improve therapeutic outcomes, prolong life and quality of life are our main business. We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics

Close Menu